152 related articles for article (PubMed ID: 28892414)
1. Efficacy of recombinant adenovirus expressing a fusion gene from GM-CSF and Epstein-Barr virus LMP2A in a mouse tumor model.
Xue Q; Li X; Yang C; Ji B; Li Y; Yan Y; Yang X; Wang C; Chen T
Hum Vaccin Immunother; 2017 Oct; 13(10):2260-2268. PubMed ID: 28892414
[TBL] [Abstract][Full Text] [Related]
2. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.
Kim SY; Kang D; Choi HJ; Joo Y; Kim JH; Song JJ
Oncotarget; 2017 Feb; 8(9):15858-15877. PubMed ID: 28178658
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour research of recombinant BCG using BZLF1 and hGM-CSF fusion genes.
Xue QJ; Li YQ; Yang CQ; Chen T; Li XZ; Cheng B; Wang CM
Vaccine; 2017 Mar; 35(12):1599-1607. PubMed ID: 28228322
[TBL] [Abstract][Full Text] [Related]
4. EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A.
Yan Y; Xue QJ; Liu A; Wang H; Zhang H; Wang S; Zhao L; Li Y; Li X; Yang Y; Chen T; Li S
Hum Vaccin Immunother; 2020 Mar; 16(3):654-663. PubMed ID: 31567046
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CSF2A fusion gene and its effect on Epstein-Barr virus-positive tumor cells.
Sun Y; Long J; Yin Y; Li H; Jiang E; Zeng C; Zhu W
J Med Virol; 2018 Nov; 90(11):1750-1756. PubMed ID: 29900557
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F
Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422
[TBL] [Abstract][Full Text] [Related]
7. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells.
Sun H; Yao K; Chen Y; Zhou F
Chin Med J (Engl); 2004 Oct; 117(10):1558-63. PubMed ID: 15498383
[TBL] [Abstract][Full Text] [Related]
8. [Construction of recombinant adenovirus vector expressing extracellular domain of TbetaR-II-RANTES fusion gene and its anti-tumor effects].
Wang XD; Liu H; Cao S; Li H; Ren XB; Hao XS
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):405-10. PubMed ID: 17974270
[TBL] [Abstract][Full Text] [Related]
9. [Application of a tumor cell vaccine transfected with GM-CSF/IL-2 fusion gene for specific immunotherapy of hepatocellular carcinoma].
Guo C; Liu QG; Yang W; Yao YM
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):188-92. PubMed ID: 18250039
[TBL] [Abstract][Full Text] [Related]
10. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor.
Lee CT; Wu S; Ciernik IF; Chen H; Nadaf-Rahrov S; Gabrilovich D; Carbone DP
Hum Gene Ther; 1997 Jan; 8(2):187-93. PubMed ID: 9017422
[TBL] [Abstract][Full Text] [Related]
11. Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination.
Wang Z; Yang S; Zhou L; Du H; Mo W; Zeng Y
Sci China Life Sci; 2011 Mar; 54(3):263-6. PubMed ID: 21416326
[TBL] [Abstract][Full Text] [Related]
12. Recombinant adenovirus expressing GP5 and M fusion proteins of porcine reproductive and respiratory syndrome virus induce both humoral and cell-mediated immune responses in mice.
Jiang W; Jiang P; Li Y; Tang J; Wang X; Ma S
Vet Immunol Immunopathol; 2006 Sep; 113(1-2):169-80. PubMed ID: 16777236
[TBL] [Abstract][Full Text] [Related]
13. Construction of a recombinant-BCG containing the LMP2A and BZLF1 genes and its significance in the Epstein-Barr virus positive gastric carcinoma.
Xue QJ; Dai J; Li XZ; Zhu W; Si CP; Chen T
J Med Virol; 2014 Oct; 86(10):1780-7. PubMed ID: 24699993
[TBL] [Abstract][Full Text] [Related]
14. Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy.
Hamada K; Desaki J; Nakagawa K; Zhang T; Shirakawa T; Gotoh A; Tagawa M
Mol Ther; 2007 Jun; 15(6):1121-8. PubMed ID: 17387337
[TBL] [Abstract][Full Text] [Related]
15. [Construction and immunogenicity of recombinant adenovirus tandem expressing M and GP5 of porcine reproductive and respiratory syndrome virus].
Jiang WM; Jiang P; Li YF; Tang JY; Wang XW; Du YJ
Sheng Wu Gong Cheng Xue Bao; 2006 Jul; 22(4):555-60. PubMed ID: 16894887
[TBL] [Abstract][Full Text] [Related]
16. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines.
Inoue H; Iga M; Nabeta H; Yokoo T; Suehiro Y; Okano S; Inoue M; Kinoh H; Katagiri T; Takayama K; Yonemitsu Y; Hasegawa M; Nakamura Y; Nakanishi Y; Tani K
Cancer Sci; 2008 Nov; 99(11):2315-26. PubMed ID: 18957055
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
18. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
Fournier P; Aigner M; Schirrmacher V
Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
[TBL] [Abstract][Full Text] [Related]
19. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
